Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Accounts Payables (2016 - 2025)

Vycor Medical has reported Accounts Payables over the past 16 years, most recently at $84755.0 for Q4 2025.

  • Quarterly Accounts Payables fell 42.57% to $84755.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84755.0 through Dec 2025, down 42.57% year-over-year, with the annual reading at $84755.0 for FY2025, 42.57% down from the prior year.
  • Accounts Payables was $84755.0 for Q4 2025 at Vycor Medical, down from $92821.0 in the prior quarter.
  • Over five years, Accounts Payables peaked at $227720.0 in Q4 2021 and troughed at $84755.0 in Q4 2025.
  • The 5-year median for Accounts Payables is $152875.0 (2024), against an average of $158412.1.
  • Year-over-year, Accounts Payables skyrocketed 43.82% in 2021 and then tumbled 48.07% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $227720.0 in 2021, then fell by 12.15% to $200044.0 in 2022, then tumbled by 41.11% to $117801.0 in 2023, then increased by 25.27% to $147569.0 in 2024, then plummeted by 42.57% to $84755.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Accounts Payables are $84755.0 (Q4 2025), $92821.0 (Q3 2025), and $110042.0 (Q2 2025).